Newsletter
donate now

Search Results for: Obinutuzumab – Page 3

ASH 2022: Dr. Matthew Davids on the Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL / SLL)

February 6, 2023

Our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute. They discussed the results of a new study looking at whether combining the anti-CD20 monoclonal antibody obinutuzumab with the BTK inhibitor acalabrutinib provided any additional survival benefit.

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)

January 6, 2023

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with none of the more serious  abnormal ventricular heart irregularities seen.

I Was Born for This: My Year on Obinutuzumab and Venetoclax

September 20, 2022

Whenever life throws a challenge my way, I tell myself, “I was born for this.” I reminded myself of this while I went through a year of cancer treatment. It may seem like a strange thing to say to yourself, saying you’re born to face adversity, but that’s the kind of mindset that got me through a challenging time.

ASH 2021: Dr. Jake Soumerai on Measurable Residual Disease-Guided Treatment of Chronic Lymphocytic Leukemia (CLL) with Venetoclax and Obinutuzumab plus Zanubrutinib

September 13, 2022

At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jake Soumerai, a clinical investigator at Massachusetts General Hospital and an Assistant Professor at Harvard Medical School. They discussed MRD as a biomarker to direct treatment duration in a phase 2 clinical trial of triple combination venetoclax and obinutuzumab plus zanubrutinib.

Didn't find what you where looking for?

Try our advanced search page!
Search Now!